Polyphor Announces Financial Results for the Full-Year 2020
Phase III trial patient enrollment for balixafortide completed in Q4 2020 despite COVID-19. Results expected for ORR and PFS in Q2 and Q4 2021 respectively Exclusive licensing agreement for balixafortide in China with Fosun Pharma Clinical Trial Authorization (CTA) granted by MHRA to initiate Phase...